
Opinion|Videos|May 8, 2025
Institutional Implementation: Setting Up Tarlatamab Administration
Panelists discuss how the administration of tarlatamab requires thorough pretreatment screening, staff training, and close monitoring for immune-related adverse effects such as cytokine release syndrome, emphasizing the importance of patient education, rapid intervention, and specialized infrastructure for safe and effective treatment.
Advertisement
Episodes in this series

Summary for Physicians:
Protocol for Tarlatamab Administration:
- Site Setup:
- Pretreatment screening: Ensure patients meet eligibility, assess organ function, and check for contraindications.
- Staff training: Ensure all staff are trained on administration protocols and handling potential toxicities.
- Monitoring: Patients are monitored for immune-related adverse effects such as cytokine release syndrome (CRS), especially during the first dose.
Challenges:
- Management of CRS:
- Need for rapid intervention and close monitoring in case of severe reactions.
- Patient Education:
- Ensuring patients understand potential adverse effects and the importance of timely reporting.
- Infrastructure:
Need for specialized facilities and equipment for infusion and monitoring, especially in the event of adverse reactions.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood-Based Lung Cancer Screening Tool Earns FDA Breakthrough Device Status
2
One of “The Best Opportunities” for Long-Term Remission in Multiple Myeloma
3
FDA Approves Iberdomide Combo in Relapsed/Refractory Multiple Myeloma
4
What Are The Biggest Misconceptions About CAR T Cells in Multiple Myeloma?
5















































